Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun:80:102454.
doi: 10.1016/j.cbpa.2024.102454. Epub 2024 Apr 16.

Advances in understanding and exploiting Siglec-glycan interactions

Zeinab Jame-Chenarboo  1 , Taylor E Gray  1 , Matthew S Macauley  2
Affiliations
Free article
Review

Advances in understanding and exploiting Siglec-glycan interactions

Zeinab Jame-Chenarboo et al. Curr Opin Chem Biol. 2024 Jun.
Free article

Abstract

Sialic-acid-binding immunoglobulin-type lectins (Siglecs) are a family of cell-surface immunomodulatory receptors that recognize sialic-acid-containing glycans. The majority of Siglecs have an inhibitory motif in their intercellular domain and can regulate the cellular activation of immune cells. Importantly, the immunomodulatory role of Siglecs is regulated by engagement with distinct sialoglycan ligands. However, there are still many unanswered questions about the precise ligand(s) recognized by individual Siglec family members. New tools and approaches to study Siglec-ligand interactions are rapidly filling this knowledge gap. This review provides an overview of recent advances in discovering Siglec ligands as well as the development of approaches to modulate the function of Siglecs. In both aspects, chemical biology approaches are emphasized with a discussion on how these are complementing biochemical and genetic strategies.

Keywords: Carbohydrate; Glycans; Immunomodulation; Sialic acid; Siglecs.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Matthew S Macauley reports financial support was provided by Canada Research Chairs. Taylor E Gray reports financial support was provided by Natural Sciences and Engineering Research Council of Canada. Matthew S. Macauley has patent #Targeting Siglec-6 with glycan ligands pending to University of Alberta. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Substances

LinkOut - more resources